Price to Sales (P/S)
since 2013
Calculation
IQVIA Holdings Inc., P/S, long-term trends, calculation
| P/S | = | Share price1, 2, 3 | ÷ | Sales per share1 | Sales per share1 | = | Revenues1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 15, 2023 | 2.93 | = | 227.03 | ÷ | 77.59 | 77.59 | = | 14,410 | ÷ | 185,722,621 | |
| Feb 16, 2022 | 3.19 | = | 232.18 | ÷ | 72.84 | 72.84 | = | 13,874 | ÷ | 190,485,264 | |
| Feb 12, 2021 | 3.24 | = | 192.66 | ÷ | 59.38 | 59.38 | = | 11,359 | ÷ | 191,281,286 | |
| Feb 18, 2020 | 2.87 | = | 165.42 | ÷ | 57.65 | 57.65 | = | 11,088 | ÷ | 192,339,093 | |
| Feb 19, 2019 | 2.69 | = | 141.49 | ÷ | 52.69 | 52.69 | = | 10,412 | ÷ | 197,599,861 | |
| Feb 16, 2018 | 2.18 | = | 101.72 | ÷ | 46.77 | 46.77 | = | 9,739 | ÷ | 208,251,468 | |
| Feb 16, 2017 | 2.63 | = | 76.87 | ÷ | 29.18 | 29.18 | = | 6,878 | ÷ | 235,719,111 | |
| Feb 11, 2016 | 1.23 | = | 59.00 | ÷ | 48.06 | 48.06 | = | 5,738 | ÷ | 119,384,993 | |
| Feb 12, 2015 | 1.44 | = | 63.25 | ÷ | 43.92 | 43.92 | = | 5,460 | ÷ | 124,315,113 | |
| Feb 13, 2014 | 1.33 | = | 52.20 | ÷ | 39.27 | 39.27 | = | 5,100 | ÷ | 129,842,707 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of IQVIA Holdings Inc. Annual Report.
- Share Price
- The share price exhibited a generally upward trend over the ten-year period. Starting at $52.20 in February 2014, the price increased steadily with minor fluctuations, reaching a peak of $232.18 in February 2022. In the final year, it experienced a slight decline to $227.03 by February 2023. Overall, the share price more than quadrupled during the period, indicating substantial growth in market valuation.
- Sales Per Share
- Sales per share showed fluctuations over the timeframe but maintained a general growth trajectory. Beginning at $39.27 in February 2014, it rose consistently, except for an anomalous drop to $29.18 in February 2017. After this dip, sales per share resumed growth, peaking at $77.59 in February 2023. The growth after 2017 demonstrates a recovery and continued increase in revenue generation per share.
- Price-to-Sales (P/S) Ratio
- The P/S ratio showed variability correlating with changes in share price and sales per share. Initially, it hovered around 1.3 to 1.4 from 2014 to 2016, then rose sharply to 2.63 in 2017 despite a sales per share decline, reflecting market optimism or increased valuation multiples. From 2018 onward, it maintained a higher range between 2.18 and 3.24, peaking in 2021 at 3.24 before slightly decreasing to 2.93 in 2023. This suggests the market assigned a premium to the company's sales in recent years, indicating confidence in growth prospects or profitability improvements.
- Overall Analysis
- The data reveals strong growth in both share price and sales per share over the decade, indicating improved financial performance and investor confidence. The temporary sales per share decrease in 2017 coincided with a sharp increase in the P/S ratio, implying that market valuation adjustments were not solely dependent on immediate sales figures. The consistent high P/S ratios in recent years suggest sustained positive market sentiment. The slight decline in share price and P/S ratio in the last year may warrant further monitoring but does not detract from the overall positive growth trends observed.
Comparison to Competitors
IQVIA Holdings Inc., P/S, long-term trends, comparison to competitors
| IQVIA Holdings Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 15, 2023 | 2.93 | 4.61 | 5.17 | 3.29 | 5.79 | 10.96 | 3.86 | 4.34 | 4.71 | 2.35 | 7.01 | 4.73 | 8.56 |
| Feb 16, 2022 | 3.19 | 4.53 | 5.10 | 3.16 | 6.37 | 8.01 | 2.85 | 4.66 | 3.96 | 3.15 | 4.20 | 5.39 | 8.21 |
| Feb 12, 2021 | 3.24 | 4.05 | 5.64 | 3.16 | 7.01 | 8.06 | 3.24 | 5.15 | 3.93 | 4.42 | 6.24 | 5.52 | 8.82 |
| Feb 18, 2020 | 2.87 | 4.22 | 6.03 | 5.52 | 6.29 | 6.03 | 4.00 | 4.79 | 4.33 | 3.66 | 5.34 | 4.83 | 14.95 |
| Feb 19, 2019 | 2.69 | 3.58 | 5.22 | 3.67 | 3.97 | 5.15 | 3.84 | 4.45 | 4.92 | 4.49 | 6.62 | 4.24 | 15.54 |
| Feb 16, 2018 | 2.18 | 6.67 | 5.82 | 5.02 | 3.70 | 3.71 | 4.10 | 4.56 | 3.68 | 4.05 | 5.92 | 4.01 | 16.42 |
| Feb 16, 2017 | 2.63 | 3.84 | 5.65 | 4.72 | 3.48 | 4.18 | 3.08 | 4.62 | 4.54 | 3.84 | 7.86 | 3.37 | 12.51 |
| Feb 11, 2016 | 1.23 | 3.83 | 5.28 | 6.07 | 2.91 | 4.02 | 3.80 | 4.13 | 3.56 | 3.76 | 9.38 | 3.05 | 20.38 |
| Feb 12, 2015 | 1.44 | 4.90 | 6.13 | 6.28 | 3.09 | 4.03 | 6.36 | 3.77 | 3.93 | 4.24 | 14.62 | 3.06 | 47.41 |
| Feb 13, 2014 | 1.33 | 4.31 | 5.22 | 5.48 | 2.78 | 2.81 | 11.95 | 3.63 | 3.78 | 3.97 | 15.52 | 3.74 | 16.53 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
IQVIA Holdings Inc., P/S, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| IQVIA Holdings Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 15, 2023 | 2.93 | 4.56 |
| Feb 16, 2022 | 3.19 | 4.50 |
| Feb 12, 2021 | 3.24 | 4.90 |
| Feb 18, 2020 | 2.87 | 4.88 |
| Feb 19, 2019 | 2.69 | 4.54 |
| Feb 16, 2018 | 2.18 | 4.60 |
| Feb 16, 2017 | 2.63 | 4.29 |
| Feb 11, 2016 | 1.23 | 4.10 |
| Feb 12, 2015 | 1.44 | 4.54 |
| Feb 13, 2014 | 1.33 | 4.30 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).
Comparison to Industry (Health Care)
IQVIA Holdings Inc., P/S, long-term trends, comparison to industry (health care)
| IQVIA Holdings Inc. | Health Care | |
|---|---|---|
| Feb 15, 2023 | 2.93 | 51,413.66 |
| Feb 16, 2022 | 3.19 | 3.28 |
| Feb 12, 2021 | 3.24 | 3.31 |
| Feb 18, 2020 | 2.87 | 3.21 |
| Feb 19, 2019 | 2.69 | 3.07 |
| Feb 16, 2018 | 2.18 | 3.06 |
| Feb 16, 2017 | 2.63 | 2.80 |
| Feb 11, 2016 | 1.23 | 2.72 |
| Feb 12, 2015 | 1.44 | 3.08 |
| Feb 13, 2014 | 1.33 | 2.81 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).